Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when INSP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsInspire Medical reports Q2 revenue decline, raises guidance, launches $30M growth plan
Filed August 3, 2026 · Period ending August 3, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 revenue fell 7.6% YoY to $200.6M due to U.S. coding and reimbursement challenges; company raised full-year revenue guidance to $835M-$875M and adjusted EPS to $1.05-$1.45, signaling confidence despite headwinds.
Item 2.02 verify on EDGAR → -
high
Announced Project Horizon restructuring to unlock $30M in annualized growth investment capacity; expects $20M-$25M in pre-tax charges ($4M-$5M employee-related, $16M-$20M non-cash), with most actions complete by Q3 2026.
Exhibit 99.1 view on EDGAR → -
medium
Gross margin expanded 150 bps to 85.5% driven by favorable product mix toward higher-margin Inspire V system; Q2 operating cash flow improved to $23.2M from $2.7M prior year.
Exhibit 99.1 view on EDGAR → -
medium
Achieved Q2 diluted EPS of $0.01 and adjusted diluted EPS of $0.14, reflecting improved profitability versus prior-year loss despite revenue decline.
Exhibit 99.1 view on EDGAR → -
low
Furnished investor presentation materials for August-September 2026 meetings; routine Regulation FD disclosure with no new business updates.
Item 7.01 verify on EDGAR →
Summary
Inspire Medical Systems reported mixed Q2 2026 results, with revenue declining 7.6% year-over-year to $200.6 million due to ongoing U.S. coding and reimbursement challenges affecting its obstructive sleep apnea therapy business.
Despite the top-line pressure, the company achieved profitability with diluted EPS of $0.01 and adjusted diluted EPS of $0.14, supported by 150 basis points of gross margin expansion to 85.5% as sales shifted toward the higher-margin Inspire V system. Operating cash flow improved sharply to $23.2 million from $2.7 million in the prior-year quarter, driven by better working capital management.
Management raised full-year 2026 guidance, now expecting revenue of $835 million to $875 million and adjusted EPS of $1.05 to $1.45, signaling confidence in navigating reimbursement headwinds. The company announced Project Horizon, a strategic restructuring plan designed to unlock approximately $30 million in annualized growth investment capacity by streamlining operations and consolidating supply chain production. Inspire expects to incur $20 million to $25 million in pre-tax restructuring charges, with most actions completed by the end of Q3 2026. The plan aims to reallocate resources toward revenue growth initiatives while improving operational efficiency. Retail investors should monitor whether the restructuring delivers the promised growth investment capacity and whether reimbursement challenges stabilize in coming quarters.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Inspire Medical announced Q2 2026 financial results via press release.
Added in current filing · verify on EDGAR →
On August 3, 2026, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026.
The company disclosed its second quarter 2026 financial results through a press release. The 8-K body does not provide specific financial metrics; those details are contained in the attached Exhibit 99.1 press release.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In August and September of 2026, the Company will be participating in various meetings with investors and analysts, and a copy of the Company’s presentation materials being used at these meetings is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.
The company furnished presentation materials for investor and analyst meetings scheduled in August and September 2026. The materials are available on the company's investor relations website. This is a routine disclosure under Regulation FD to ensure equal access to information presented at investor meetings.
Event · Exhibit 99.1
Inspire Medical Systems reported Q2 2026 results, raised full-year guidance, and announced a $30M strategic growth plan (Project Horizon).
Added in current filing · view on EDGAR →
Generated second quarter revenue of $200.6 million
•Second quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14
Inspire Medical Systems reported Q2 2026 revenue of $200.6 million, down 7.6% year-over-year, primarily due to U.S. revenue declines driven by evolving coding and reimbursement challenges. Despite the revenue decline, the company achieved diluted EPS of $0.01 and adjusted diluted EPS of $0.14, reflecting improved profitability versus the prior year's loss.
Added in current filing · view on EDGAR →
The Company is raising its previously announced revenue outlook to be in the range of $835 million to $875 million. Additionally, the Company now expects annual adjusted operating margin to be in the range of 4% to 6%, diluted EPS to be in the range of $(0.42) to $0.17 and adjusted diluted EPS to be in the range of $1.05 to $1.45.
Inspire raised its full-year 2026 revenue guidance to $835 million to $875 million and now expects adjusted operating margin of 4% to 6%, diluted EPS of $(0.42) to $0.17, and adjusted diluted EPS of $1.05 to $1.45. The guidance raise signals management confidence despite ongoing reimbursement headwinds.
Added in current filing · view on EDGAR →
On August 3, 2026, the Company announced a strategic growth plan, named Project Horizon, intended to create additional investment capacity to accelerate revenue growth through:
•Aligning resources to revenue growth initiatives;
•Streamlining the organization; and
•Optimizing the Company's supply chain by consolidating production to support quality, scale, and efficiency.
The Company expects to incur a total of $20 million to $25 million of pre-tax restructuring charges in connection with the first phase of Project Horizon, including approximately $4 million to $5 million of employee-related costs, and $16 million to $20 million of other expenses, which will be non-cash in nature. These actions are expected to generate approximately $30 million of annualized growth investment capacity which is expected to be invested in revenue growth initiatives.
Inspire announced Project Horizon, a strategic growth plan designed to unlock approximately $30 million in annualized growth investment capacity by streamlining operations, aligning resources to revenue growth, and optimizing the supply chain. The company expects to incur $20 million to $25 million in pre-tax restructuring charges ($4-5 million employee-related, $16-20 million non-cash), with most actions completed in Q3 2026 and all substantially complete by year-end.
Added in current filing · view on EDGAR →
Gross margin increased 150 bps to 85.5%, primarily due to increased sales mix of the Inspire V system, which has a higher gross margin than the Inspire IV system.
Gross margin expanded 150 basis points to 85.5% in Q2 2026, driven by a favorable product mix shift toward the higher-margin Inspire V system. This margin improvement partially offsets the revenue headwinds and supports profitability.
Event · Exhibit 99.2
Inspire Medical Systems filed an investor presentation disclosing Q2 2026 results, full-year guidance, and a $30M strategic growth plan.
Added in current filing · view on EDGAR →
Generated second quarter revenue of $200.6 million • Second quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14 • Second quarter operating cash flow of $23.2 million
Inspire Medical Systems reported Q2 2026 revenue of $200.6 million, GAAP diluted EPS of $0.01, adjusted diluted EPS of $0.14, and operating cash flow of $23.2 million. These results reflect the company's ongoing commercial expansion of its Inspire therapy system for obstructive sleep apnea.
Added in current filing · view on EDGAR →
2026 Guidance: • FY2026 revenue range of $835M-$875M • FY2026 Adjusted operating income margin between 4%-6% • FY2026 Adjusted EPS $1.05-$1.45
The company provided full-year 2026 guidance with revenue expected between $835 million and $875 million, adjusted operating income margin of 4% to 6%, and adjusted EPS of $1.05 to $1.45. This guidance reflects expectations for continued growth in the Inspire therapy business.
Added in current filing · view on EDGAR →
Announced strategic growth plan to deploy $30 million into growth initiatives
Inspire Medical Systems announced a strategic growth plan involving a $30 million deployment into growth initiatives. The presentation indicates this investment is intended to support revenue growth initiatives, though specific allocation details are not disclosed in the filing.
Added in current filing · view on EDGAR →
Steady progress on the full launch of the Inspire V system in the U.S. • 3T MRI compatibility
The company reported steady progress on the full U.S. launch of its Inspire V neurostimulator system, which features 3T MRI compatibility. The presentation indicates Inspire V has been approved by the FDA and is being rolled out commercially, representing the next generation of the company's core product.
Added in current filing · view on EDGAR →
Independent study from VCU of cardiovascular and respiratory outcomes comparing Inspire to CPAP and no therapy
An independent study from Virginia Commonwealth University compared cardiovascular and respiratory outcomes for Inspire therapy versus CPAP and no therapy. This third-party clinical evidence supports the company's value proposition for its neurostimulation treatment of obstructive sleep apnea.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 4, 2026 · How we verify